Connect with us

Business

Benchmark Botanics Inc. (OTCMKTS:BHHKF) Announces a Share Exchange Agreement with Shareholders of 1139000 B.C. Ltd

Published

on

Benchmark Botanics Inc. (OTCMKTS:BHHKF) will be acquiring approximately 5,199,000 Common shares from 1139000 B.C. Ltd. This will be accomplished through a 5M Common shares of 1139, and the new acquisition will be in addition to another 5,000,000 Common shares Benchmark already owns from 1139. The ownership of a total of 10,199,000 Common shares will be a representation of 51% of issued and outstanding share capital of 1139.

Production of the Highest-Quality, Indoor-Grown Cannabis by Benchmark 

Benchmark’s strategy is to become a pioneer in the production and sale of medical cannabis and hemp. Its target locations include Asia and other countries where medical cannabis has been legalized. This means it has to pursue Canadian Licensing.

The only way to accomplish this is to produce high-quality cannabis, which meets the needs of patients and adult recreational consumers. The development of international business partnerships could win the company another expansion strategy. It has already established a joint venture, which has resulted in the completion of a second facility, a 4-acre Greenhouse Operation in Pitt Meadows, BC.

Benchmark’s Vision and Strategy to Position Itself at a Global Level

As cannabis continues to become legal in several regions, the Benchmark is on a trail to pursue its vision of positioning itself at a higher level globally. It is anticipating to take head on the control of the hemp and flax industry.

The company has signed a Memorandum of Understanding (MOU), which will lead to the establishment of a Comprehensive Research and Development Centre for Flax and Hemp Genetics (CFHG) center. It will work collaboratively with Researchers at the University of British Columbia, Okanagan, and together they will push the hemp and flax industry to its full potential.

Through the use of applied genomics and genetic tools, the duo will develop novel germplasm while new biotechnology, such as the CRIS PR/Cas9 system, will be used extensively to modify metabolic pathways.

“CFHG will strengthen collaborations between Canada and other parts of the world including the greater China regions…’’ William Ying, CEO, Benchmark Botanics, reported.

The two parties will also benefit from each other through personnel exchange. By opening the Canadian hemp products to the Chinese market, they will also be bridging business to reach the global market.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.